Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 149.32MWorking Capital
VS
Market
Sector
Industry
History
$ 16.95Close
$ 3.93 - $ 21.42 52-Week Range
Ticker Information
Ticker
URGNCompany Name
UROGEN PHARMA LTDSector
HealthcareIndustry
BiotechnologyExchange
NASDAQUROGEN PHARMA LTD - Working Capital Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
URGN - Working Capital Historical data
| Date | Current Assets | Current Liabilities | Working Capital |
|---|---|---|---|
| 6/30/2025 | $ 196.87M | $ 47.55M | $ 149.32M |
| 3/31/2025 | $ 237.18M | $ 42M | $ 195.18M |
| 12/31/2024 | $ 276.13M | $ 45.95M | $ 230.19M |
| 9/30/2024 | $ 295.1M | $ 32.79M | $ 262.31M |
| 6/30/2024 | $ 278.97M | $ 34.22M | $ 244.75M |
| 3/31/2024 | $ 196.76M | $ 26.34M | $ 170.42M |
| 12/31/2023 | $ 169.19M | $ 31.21M | $ 137.97M |
| 9/30/2023 | $ 182.12M | $ 25.79M | $ 156.34M |
| 6/30/2023 | $ 81.33M | $ 26.77M | $ 54.57M |
| 3/31/2023 | $ 95.97M | $ 25.23M | $ 70.74M |
Key Performance Insights, Last 5 Years
- UROGEN PHARMA LTD's latest trailing twelve months (TTM) Working Capital stands at $ 111.72M.
- Over the past 5 years, UROGEN PHARMA LTD's average Working Capital has been $ 137.16M.
- The median Working Capital for UROGEN PHARMA LTD during this period was $ 121.51M
- UROGEN PHARMA LTD reached its highest Working Capital over the past 5 years at $ 262.31M.
- The lowest Working Capital recorded by UROGEN PHARMA LTD in the same timeframe $ 54.57M
UROGEN PHARMA LTD's Working Capital vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Working Capital Benchmarks
Similar metrics to Working Capital:
- Current Ratio - [Calculation] The current ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations due within one year. Calculated by dividing current assets [AssetsC] by current liabilities [LiabilitiesC].
- Quick Ratio - [Calculation] The quick ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations without the need to sell its inventory or receive additional financing. Calculated by dividing current assets [AssetsC] minus [Inventory] by current liabilities [LiabilitiesC].
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Working Capital
[Calculation] The working capital represents the capital used in day-to-day operations. It is the difference between a company’s short-term assets [AssetsC] and current liabilities [LiabilitiesC].AssetsC - LiabilitesC
(=) Working Capital Working Capital for UROGEN PHARMA LTD is calculated as follows: AssetsC [ $ 129.34M ] - LiabilitesC [ $ 17.62M ]
(=) Working Capital [ $ 111.72M ] URGN - Working Capital, Last 5 years
$ 54.57M
Minimum
Jun 30, 2023
$ 262.31M
Maximum
Sep 30, 2024
$ 137.16M
Average
$ 121.51M
Median
Working Capital Benchmark AnalysisMarket
The chart above depicts the distribution of Working Capital for companies in the Total Stock Market. The average Working Capital of the companies is $ 96.42M with a standard deviation of $ 173.65M.
The following table provides additional summary stats:
Working Capital in the Market:
| filtered constituents | 2.79K |
|---|---|
| min | $ -457.39M |
| max | $ 607.04M |
| average | $ 96.42M |
| median | $ 32.11M |
| std | $ 173.65M |